Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13811MR)

This product GTTS-WQ13811MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13811MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6522MR IVTScrip™ mRNA-Anti-ALCAM, CX-191(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CX-191
GTTS-WQ13525MR IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PRX-003
GTTS-WQ14275MR IVTScrip™ mRNA-Anti-CSF1R, RG7155(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG7155
GTTS-WQ12849MR IVTScrip™ mRNA-Anti-FZD10, ONC-005(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ONC-005
GTTS-WQ2009MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA AGT-181
GTTS-WQ11446MR IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-9447
GTTS-WQ11263MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI4736
GTTS-WQ7583MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW